Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

OSTXBullishCorporate Developmentsnews

High materiality7/10

OSTX raises funds to advance Herlystic regulatory submissions in 4Q2026

Oct 19, 2026, 5:56 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The financing event and tax credits improve cash runway, enabling critical 4Q2026 regulatory filings; potential PRV monetization adds optional upside; dilutive effects are partially offset by rapid new warrants at modest strike.

AI summary

What happened, with direct paths to the underlying reporting

OS Therapies announced an initial warrant inducement closing, raising $7.2M gross and $7M UK R&D tax credits, extending runway toward key 2026 milestones. The company intends 4Q2026 BLA submission to FDA and CMAAs to MHRA/EMA/TGA for Herlystic, with potential Priority Review Voucher monetization, depending on regulatory outcomes.

OSTX raises $7.2M gross from warrant inducement.
Initial closing expands runway toward major 4Q2026 milestones.
R&D tax credits of $7M expected early 2027.
OSTX plans 4Q2026 BLA/CMAA submissions for Herlystic.
PRV sale potential cited; last PRV sale was $203M in Oct 2026.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

OSTX raises funds to advance Herlystic regulatory submissions in 4Q2026

OSTX OST-HER2 Phase 2b shows strong 3-year survival; regulatory path accelerates

OSTX Appoints CCO and CFO to Accelerate Herlystic commercialization

OST-HER2 shows strong survival signal; regulatory path aligned for accelerated approval

OS Therapies Discloses 2026 Timeline For Lead Drug Regulatory Filings